-
EZ Cap™ Mouse IL-7 mRNA Guide
2026-09-30
EZ Cap™ Mouse IL-7 mRNA (m1Ψ, HA tag) is an expression reagent designed to produce mouse interleukin-7 while enabling HA-directed detection. Its modified-nucleoside format supports a testable workflow for delivery, translation, and cytokine-response studies, but the supplied dossier does not establish dose, potency, formulation, or in vivo efficacy.
-
N1-Methylpseudouridine for CRISPRa mRNA Workflows
2026-09-30
N1-Methylpseudouridine can support a practical comparison of mRNA chemistries in CRISPR activation assays, where robust dCas9-VPR expression must be separated from splice-specific biology. This guide connects modified-nucleoside handling with fibroblast-based variant analysis, control design, and troubleshooting for reproducible protein expression and RNA readouts.
-
ML-210 and the Radical Logic of Ferroptosis
2026-09-29
A translational framework for using ML-210 to interrogate ferroptosis alongside STING signaling, informed by evidence that H-151 combines STING inhibition with radical-trapping antioxidant activity in renal ischemia-reperfusion injury.
-
Enhanced EZ Cap™ EGFP mRNA: Assay Design
2026-09-29
Enhanced EZ Cap™ EGFP mRNA (m1Ψ) provides a practical reporter framework for dissecting RNA delivery, translation, and nanoparticle performance. This article connects reporter assay design with the programmable potato virus X platform described in recent research.
-
HyperScript™ cDNA for GlmS–sigB Assays
2026-09-28
Discover how the HyperScript First-Strand cDNA Synthesis Kit can support rigorous RNA analysis of the GlmS–sigB regulatory axis in Staphylococcus aureus. This article translates a mechanistic biofilm study into practical decisions about RNA input, primer selection, controls, and qPCR interpretation.
-
2'-O-Methyladenosine: Evidence and Research Use
2026-09-28
2'-O-Methyladenosine is an adenosine nucleoside modified at the ribose 2′-oxygen, making it distinct from adenine-base methylation. A 2024 stable isotope-diluted UHPLC–MS/MS study supports sensitive analysis of methylated purine nucleosides, but does not establish specific biological effects for this compound.
-
EDC.HCl: Practical Coupling Workflow and QC
2026-09-27
EDC.HCl activates carboxyl groups for amide-bond formation with primary amines in peptide synthesis and bioconjugation workflows. This guide covers handling and reaction setup for in vitro research; the supplied dossier reports no in vivo or clinical data.
-
CRISPRa Reveals Splice Effects in Accessible Cells
2026-09-26
Terkelsen and colleagues used CRISPR activation to induce disease-gene expression in patient-derived skin fibroblasts, enabling splice analysis for genes normally expressed in less accessible tissues. Their proof-of-principle study shows how targeted gene induction can extend RNA diagnostics while highlighting the need to validate results in the context of each gene and variant.
-
Azide-Enabled Cap-Independent mRNA Translation
2026-09-25
Golojuch and colleagues report a 5′-end modification strategy that combines azide-modified dinucleotide priming during transcription with post-transcriptional click chemistry. In the tested systems, this approach improved cap-independent mRNA stability and protein output without detectable immunogenicity, offering a tool for studying and developing linear mRNAs that do not rely on a 5′ cap.
-
TBST Workflows for Cleaner Cancer Immunoassays
2026-09-25
Use TBST to standardize antibody blocking, dilution, and washing in cancer assays without confusing cleaner detection with stronger biology. This guide connects practical TBST workflows to uPAR–uPA metastasis research and highlights where detergent-sensitive controls are essential.
-
Pseudo-UTP for Reliable Modified mRNA Synthesis
2026-09-24
Use Pseudo-UTP to test whether pseudouridine incorporation improves the performance of your in vitro transcribed RNA—not as a substitute for careful template, purification, and delivery controls. This workflow pairs a controlled nucleotide-replacement series with practical QC and explains what a recent retrotransposon-repair study can, and cannot, tell RNA researchers.
-
EZ Cap™ Cas9 mRNA (m1Ψ): Control the Editing Window
2026-09-24
EZ Cap™ Cas9 mRNA (m1Ψ) combines Cap1 capping and m1Ψ modification in a transient Cas9-expression format. This article explains how delivery format, expression timing, and the limits of nuclear-export research shape rigorous CRISPR-Cas9 assay design.
-
Mouse Interleukin-12 mRNA: Practical Workflow
2026-09-23
Use Mouse Interleukin-12 mRNA to study cytokine expression and immune-cell responses in mouse-relevant systems, with a Cap 1 structure, m1Ψ modification, and poly(A) tail built into the transcript. This practical workflow pairs dose and time-course optimization with controls that help separate transfection performance from IL-12 biology.
-
QPRT, PLC Signaling, and Breast Cancer Invasion
2026-09-23
Liu et al. identified QPRT as a promoter of breast cancer migration and invasion and linked this phenotype to purinergic signaling, Rho/ROCK activity, PLC, MLCK, and myosin light chain phosphorylation. The study positions U-73122 as one pharmacologic probe within a broader mechanistic framework, while also showing why genetic perturbation and pathway-level validation are essential for interpreting phospholipase C involvement.
-
Circular RNA Vaccines: Innovation, Evidence, and Limits
2026-09-22
The reference review presents circular RNA as a potentially more stable, nonintegrating platform for antigen expression, emphasizing its covalently closed structure, internal ribosome entry sites, and emerging applications in infectious disease and cancer. It also shows that production, purification, delivery, and clinical validation remain unresolved, making circRNA a promising but still early-stage technology.